I would imagine that they can differentiate how ma

I would imagine that they can differentiate how many severed and how many critical patients in each arm of the trial. Trail design is overall mortality reduction with mixed patients. However if we show a more significant mortality decline in Critically I’ll patients than FDA will have enough data for an EUA with maybe a full trial, or we may knock it put of park with some of the secondary endpoints which would
Also be worthy of an EUA, this all made more possible from the fact that over 1000 patients over 5+ period of time constantly getting the same leronlimab drug with little to no SAE’s.